On April 18, 2026, President Donald Trump signed an executive order aimed at accelerating research, regulatory review, and potential access to psychedelic-based treatments—particularly focusing on ibogaine—for serious mental health conditions. The order directs agencies like the Food and Drug Administration to fast-track clinical evaluations of these substances, which are currently classified as Schedule I drugs, and to begin planning for quicker rescheduling if they prove safe and effective in trials. It also allocates federal funding (about $50 million) to support research, especially targeting conditions such as PTSD, depression, and addiction, with a strong emphasis on helping military veterans.
More broadly, the order signals a significant policy shift toward exploring psychedelics as legitimate medical treatments after decades of strict prohibition. While it does not legalize ibogaine or bypass standard FDA approval requirements, it lowers barriers to research, expands clinical trials, and encourages coordination across federal agencies to develop therapeutic pathways. Supporters frame it as a breakthrough for treatment-resistant mental illness and a response to the veteran suicide crisis, while critics caution that the science is still emerging and highlight potential safety risks and ethical concerns tied to rapid commercialization.